FABP4 and lymphedema: Pharmacological inhibition of FABP4 with BMS markedly reduced lipid accumulation in HSFD-fed lymphedema mice, reaching levels comparable to those observed in sham-operated or CD-switched animals (Fig. EV4A,B).